Transcode Therapeutics (RNAZ) Market Capitalization (2021 - 2026)

Transcode Therapeutics (RNAZ) has reported Market Capitalization for 6 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 3.39% year-over-year to $6.3 million; the trailing twelve-month figure through Jun 2026 stood at $6.3 million (down 3.39% YoY), and the FY2025 full-year result was $4.7 million, down 85.98% from the prior year.
• Market Capitalization slipped to $6.3 million in Q2 2026 per RNAZ's latest filing, from $7.9 million in the prior quarter.
• Across five years, Market Capitalization topped out at $41.9 billion in Q1 2022 and bottomed at $4.7 million in Q4 2025.
• Historically, Market Capitalization has averaged $5.4 billion across 5 years, with a median of $157.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Market Capitalization plunged 99.66% in 2023, then rose 1.59% in 2024.
• Over 5 years, Market Capitalization stood at $9.8 billion in 2022, then slumped by 99.66% to $33.1 million in 2023, then rose by 1.59% to $33.6 million in 2024, then slumped by 85.98% to $4.7 million in 2025, then jumped by 33.35% to $6.3 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $6.3 million, $7.9 million, and $4.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.